Lihong Liu

机构：Hebei Medical University, Kunming Medical University, Fourth Hospital of Hebei Medical University, Shenzhen University Health Science Center, Shenzhen Second People's Hospital, Southern Medical University · ORCID：0009-0001-3308-1332

发表论文 104 篇 · 总被引 2397 次 · h-index 17

代表论文

• Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial (2025 · Cancer · 被引 11)
• Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma (2024 · Signal Transduction and Targeted Therapy · 被引 11)
• ATF6 activation promotes tumorigenesis and drug resistance in diffuse large B-cell lymphoma (DLBCL) by regulating the mTOR/S6K signaling pathway (2025 · Discover Oncology · 被引 9)
• Tumor immune microenvironment remodeling and prognosis of patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy with and without immunotherapy: a retrospective cohort study (2024 · Journal of Thoracic Disease · 被引 8)
• Activation of Notch-1 signaling pathway in macrophages to secrete PD-L1 and regulate cytotoxicity of CAR-T cells in diffuse large B-cell lymphoma (2024 · Aging · 被引 7)
• A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma (2025 · Journal of Hematology & Oncology · 被引 5)